Protagonist Therapeutics Inc.
PTGX | NASDAQ
$146.29
+$1.31 (+0.90%)
Sep 22, 2026, 11:19 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -42.60 | 8.64 | -16.50 | -4.33 | -12.91 | -10.50 |
PEG Ratio | 0.29 | -0.02 | 0.37 | 0.88 | -0.34 | 0.30 |
PS Ratio | 120.66 | 5.47 | 21.69 | 20.13 | 57.91 | 24.22 |
PB Ratio | 9.03 | 3.52 | 3.87 | 2.48 | 5.28 | 2.48 |
P/FCF Ratio | 99.01 | 13 | -18.37 | -4.91 | -14.54 | -9.50 |
P/OCF Ratio | 96.28 | 12.91 | -18.53 | -4.95 | -14.69 | -9.57 |
OCF/S Ratio | 125.33 | 42.39 | -117.06 | -406.82 | -394.29 | -253.19 |
Debt / Equity Ratio | 0.02 | 0.02 | 0 | 0.02 | 0.02 | 0.02 |
Quick Ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 |
Current Ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 |
Asset Turnover | 0.07 | 0.58 | 0.17 | 0.11 | 0.08 | 0.09 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | -107.89 |
Return on Equity | -21.17% | 40.75% | -23.45% | -59.09% | -41.85% | -23.66% |
Return on Assets | -19.43% | 36.95% | -22.06% | -51.38% | -36.11% | -20.39% |
Return on Invested Capital | -25.23% | 35.69% | -27.72% | -59.92% | -41.14% | -22.58% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 97.34% | 100% | 100% | 100% | 100% | 100% |
Net Profit Margin | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% | -231.07% |
Pretax Profit Margin | -281.01% | 64.32% | -131.59% | -479.26% | -458.94% | -226.51% |
Operating Profit Margin | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% | -225.36% |
FCF Margin | 121.87% | 42.08% | -118.08% | -409.81% | -398.31% | -254.84% |
EBITDA Margin | -278.35% | 64.51% | -126.07% | -466.59% | -448.79% | -222.05% |
Add to Watchlist
Select watchlists to add or remove PTGX